잠시만 기다려 주세요. 로딩중입니다.

Kallikrein 5 overexpression is associated with poor prognosis in uterine cervical cancer

Journal of Gynecologic Oncology 2020년 31권 6호 p.78 ~ 78
장지석, 김나리, 김지예, 도성임, Cho Yeon-A, 김현수, 김용배,
소속 상세정보
장지석 ( Chang Jee-Suk ) - Yonsei University College of Medicine Yonsei Cancer Center Department of Radiation Oncology
김나리 ( Kim Na-Lee ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Radiation Oncology
김지예 ( Kim Ji-Ye ) - Inje University Ilsan Paik Hospital Department of Pathology
도성임 ( Do Sung-Im ) - Sungkyunkwan University School of Medicine Kangbuk Samsung Hospital Department of Pathology
 ( Cho Yeon-A ) - Yonsei University College of Medicine Gangnam Severance Hospital Department of Radiation Oncology
김현수 ( Kim Hyun-Soo ) - Sungkyunkwan University School of Medicine Samsung Medical Center Department of Pathology and Translational Genomics
김용배 ( Kim Yong-Bae ) - Yonsei University College of Medicine Yonsei Cancer Center Department of Radiation Oncology

Abstract


Objective: Kallikrein 5 (KLK5), which is frequently observed in normal cervico-vaginal fluid, is known to be related to prognosis in several solid tumors. We investigated the prognostic significance of KLK5 in uterine cervical cancer using tumor tissue microarray and immunohistochemistry staining.

Methods: We analyzed samples of 165 patients with uterine cervical cancer who received definitive radiation therapy between 2004 and 2012. We divided patients into two groups stratified by their KLK5 activity by immunohistochemistry staining: negative/weak (0?1+) (n=120 patients) and moderate/strong (2?3+) group (n=45 patients). Patient and tumor characteristics, patterns of failure, and survival outcomes were compared. Univariable and multivariable analyses were performed to identify prognostic factors.

Results: Patients with KLK5 2?3+ were younger (median: 52 vs. 60 years) and had frequent paraaortic lymph node involvement (40.0% vs. 18.3%) than those with KLK5 0?1+. With a median follow-up of 60.8 (interquartile range, 47.5?77.9) months, patients with KLK5 2?3+ had inferior 5-year locoregional recurrence-free survival and distant metastasis-free survival of 61.7% (vs. 77.5% in KLK5 0?1+ group) and 59.4% (vs. 72.8% in the KLK5 0?1+ group), respectively (all p<0.05). KLK5 2?3+ expression retained its significance after adjusting for other well-known prognostic factors of tumor size and stage in multivariable analysis.

Conclusions: KLK5 overexpression is associated with the aggressiveness of cervical cancer and may underlie the diminished response to conventional treatments. Therefore, KLK5 could be a reliable prognostic factor in cervical cancer.

키워드

Uterine Cervical Cancer; Kallikreins; Radiation Therapy; Prognosis

원문 및 링크아웃 정보

등재저널 정보

SCI(E)
MEDLINE
KCI
KoreaMed
KAMS